Software as a Medical Device: FDA Requirements, Verification & Validation, and the Path to Market

When an Algorithm Became the Diagnosis

Consider a patient whose wearable ECG identifies previously undetected atrial fibrillation, prompting clinical follow-up and preventive treatment. This type of scenario illustrates the growing impact of Software as a Medical Device (SaMD).

That algorithm was the regulated medical device itself—a classic example of Software as a Medical Device (SaMD), a rapidly growing category of digital health products regulated under evolving FDA SaMD regulatory requirements.

What Is Software as a Medical Device (SaMD)?

Understanding the SaMD classification framework is critical because regulatory obligations, validation requirements, and market pathways are all determined by the risk level and intended medical use of the software.

The IMDRF defines SaMD as software that performs medical purposes without being part of a hardware medical device. In practice, if your software is analyzing patient data and its output influences a clinical decision, it is almost certainly regulated. Three characteristics generally define SaMD: a medical purpose, independence from dedicated medical hardware, and outputs that influence patient management.

The line between a wellness app and a regulated device is thinner than most developers expect. Regulatory authorities provide clear criteria for determining where that distinction exists.

• Diagnostic AI (radiology, dermatology, pathology)
• Clinical decision support that drives treatment choices
• Sepsis early-warning and deterioration alerts
• CGM insulin dosing recommendation software
• Mental health risk stratification tools

Medical Device Software Validation in Practice: A Continuous Glucose Monitor (CGM) Case Study

This project demonstrates how successful medical device software validation and risk-based testing contribute to a streamlined 510(k) submission for SaMD products.

Infiligence led end-to-end verification and validation for a Class II Continuous Glucose Monitor (CGM) software platform — a SaMD that interprets real-time glucose sensor data to guide insulin dosing decisions for diabetic patients. This is what a clean submission looks like in practice.

CGM SaMD: Validation Scope and Outcomes

• Classification/Intended Use: Class II 510(k) – targeted for adult Type 1 & Type 2 diabetics in an ambulatory care setting; clearly stated that this is an aid in decision making and not a substitute.
• Risk Management (ISO 14971): 47 hazard scenarios modeled — sensor drift, connectivity failure, erroneous glucose alerts, and algorithm edge cases during hypoglycemia. Controls embedded in algorithm logic, UI design, and labeling.
• Verification: 1,200+ test cases covering glucose parsing, alert threshold logic, trend accuracy, and EHR data push via HL7 FHIR R4.
• Algorithm Validation: Retrospective validation on 18 months of de-identified data from 3,400 patients — sensitivity/specificity for hypoglycemia detection stratified by age cohort and HbA1c baseline.
• Usability Engineering (IEC 62366): Formative and summative studies with 24 participants (endocrinologists, diabetes nurses, patients) — focused on alert interpretation and override workflows.
• Cybersecurity: SBOM generated for 94 components; 3 medium-severity vulnerabilities identified and remediated pre-submission; audit trail validated for CFR Part 11 compliance.
• IQ/OQ/PQ: Full installation, operational, and performance qualification on AWS GovCloud with HIPAA BAA in place.

Outcome: Clearance of 510(k) with no FDA issues in terms of the Verification & Validation package – as traceability was constructed from sprint one and rather than last minute assembling shortly before submission.

Common FDA Pathways for SaMD

• 510(k)
• De Novo
• PMA
• Enforcement discretion

Understanding FDA SaMD Regulatory Requirements and Global Compliance Pathways

Navigating FDA SaMD regulatory requirements requires a clear understanding of device risk, intended use, and post-market obligations across global regulatory frameworks.

Risk drives everything in SaMD regulation. The SaMD risk categorization framework developed by IMDRF determines the level of regulatory scrutiny required throughout the product lifecycle.

The IMDRF framework scores devices on two axes: how critical the software's output is and how severe the clinical condition it addresses. A Category IV device — one driving immediate life-or-death decisions — faces maximum scrutiny. Category I faces the least. Every regulatory strategy starts here.

North America holds ~45% of global SaMD revenue, but Asia-Pacific is the fastest-growing region. Japan's PMDA, Australia's TGA, and China's NMPA each have distinct pathways but broadly follow IMDRF principles.

A multi-jurisdictional compliance architecture built from day one costs a fraction of what it takes to retrofit one after a single-market submission.

Four Engineering Disciplines Essential for AI-Based SaMD Compliance

Most SaMD programs that hit regulatory trouble generally fail because compliance is treated as a finish line rather than a foundation. A ransomware attack on a clinical decision support system should be considered a clinical incident. A risk file that hasn't been updated since the architecture phase doesn't protect patients or submissions. These four disciplines must be present from sprint one, not retrofitted at month eighteen.

Non-Negotiable from Sprint One

• Traceability: Traceability is also a core requirement under the IEC 62304 software lifecycle standard, helping demonstrate complete coverage between requirements, implementation, and testing.
• Risk Management (ISO 14971): Not a document you complete at kickoff — a living file updated at every design change, every post-market complaint, and every architecture decision. The risk file regulators assess is the one that reflects the product you actually built.
• Verification & Validation: Effective medical device software validation combines verification, validation, usability testing, medical device cybersecurity assessments, and clinical evidence generation to support digital health regulatory compliance.
• Cybersecurity by Design: As AI and connected medical devices become more prevalent, cybersecurity has become a critical component of AI-based SaMD compliance and FDA review processes. CFR Part 11-compliant, tamper-evident audit trails. Penetration testing before submission — not a month after launch when a vulnerability researcher finds what you missed.

AI/ML Medical Devices: Ethics, Equity, and Emerging FDA Expectations

Regulatory expectations for AI/ML medical devices are evolving rapidly, with increased focus on transparency, bias mitigation, explainability, and patient safety.

Do your patients know an algorithm contributed to their diagnosis? When an AI recommendation leads to a missed finding, who is accountable — the developer, the clinician, or the hospital? These aren't hypothetical questions. They are active discussions at the FDA, in the EU Parliament, and in litigation.

FDA guidance and AI/ML policy initiatives increasingly emphasize evaluation of performance across demographic subgroups, including sex, age, and race/ethnicity. An algorithm that performs at 94% accuracy overall but 78% accuracy in one demographic cohort is not a high-performing product — it is a product with an undisclosed safety signal. Building equitable SaMD means curating diverse training data, auditing for disparate performance, and publishing the limitations of your validated population in the labeling.

These obligations are becoming regulatory expectations. The companies building for equity now won't be scrambling to retrofit it when the guidance lands.

Meeting these obligations — across traceability, risk, validation, cybersecurity, usability, and equity — requires engineering infrastructure most pharma organizations don't have fully in-house. That's not a criticism; it's the reality of how the industry is structured. It's also why the right partner makes the difference between a program that clears and one that stalls.

The Total Product Lifecycle Approach for SaMD

Regulators increasingly expect organizations to manage SaMD products through a Total Product Lifecycle (TPLC) approach. This means compliance does not end after clearance or approval. Organizations must continuously monitor performance, manage risks, validate updates, and maintain cybersecurity controls throughout the product's lifecycle.

Building Regulatory-Compliant SaMD Platforms with Infiligence

Successfully navigating SaMD development requires more than regulatory knowledge. Organizations must align quality systems, software engineering, validation, cybersecurity, and post-market processes into a single operating model.

Infiligence helps medical device manufacturers, digital health companies, and Life Sciences organizations build, validate, and scale Software as a Medical Device (SaMD) solutions. Our expertise spans FDA SaMD regulatory requirements, medical device software validation, cloud-native platform engineering, cybersecurity, and quality-focused DevSecOps.